Cas:146844-02-2 h-d-glu(obzl)-obzl hcl manufacturer & supplier

Chemical Name:h-d-glu(obzl)-obzl hcl

CAS.NO:146844-02-2

Synonyms:D-Glutaminsaeure-dibenzylester,Hydrochlorid;D-glutamic acid dibenzyl ester,hydrochloride;D-dibenzyl glutamate hydrochloride

Molecular Formula:C₁₉H₂₂ClNO₄

Molecular Weight:363.83500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.62000

Exact Mass:363.12400

LogP:4.08300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like D-Glutaminsaeure-dibenzylester,Hydrochlorid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-dibenzyl glutamate hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-glutamic acid dibenzyl ester,hydrochloride Use and application,D-Glutaminsaeure-dibenzylester,Hydrochlorid technical grade,usp/ep/jp grade.

Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). h-d-glu(obzl)-obzl hcl manufacturer Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. h-d-glu(obzl)-obzl hcl supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. h-d-glu(obzl)-obzl hcl vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. h-d-glu(obzl)-obzl hcl factory Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged.